Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma

Alexander Ulges, Norbert Hilf, Wolfgang Wick, Michael Platten, Pierre-Yves Dietrich, Katrin Frenzel, Arie Admon, Sjoerd S.H. van der Burg, Andreas von Deimling, Per thor Straten, Cecile Gouttefangeas, Judith R. Kroep, Francisco Martínez-Ricarte, Hideo Okada, Christian H. Ottensmeier, Berta Ponsati, Hans S. Poulsen, Stefan Stevanovic, Ghazaleh Tabatabai, Hans-Georg Rammensee, Ugur Sahin, Dominik Maurer and Regina Mendrzyk
Alexander Ulges
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norbert Hilf
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Wick
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Platten
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Yves Dietrich
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrin Frenzel
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arie Admon
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sjoerd S.H. van der Burg
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas von Deimling
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per thor Straten
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecile Gouttefangeas
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith R. Kroep
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Martínez-Ricarte
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideo Okada
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian H. Ottensmeier
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berta Ponsati
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans S. Poulsen
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Stevanovic
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ghazaleh Tabatabai
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Georg Rammensee
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ugur Sahin
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominik Maurer
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Regina Mendrzyk
Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A020 Published February 2019
  • Article
  • Info & Metrics
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2019 to February 2021

AbstractFull-text HTMLPDF
Total27500

Cited By

Article Information

Volume 7, Issue 2 Supplement, pp. A020

DOI 
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A020

Published By 
American Association for Cancer Research
Print ISSN 
2326-6066
Online ISSN 
2326-6074

Copyright & Usage 
©2019 American Association for Cancer Research.

Author Information

  1. Alexander Ulges,
  2. Norbert Hilf,
  3. Wolfgang Wick,
  4. Michael Platten,
  5. Pierre-Yves Dietrich,
  6. Katrin Frenzel,
  7. Arie Admon,
  8. Sjoerd S.H. van der Burg,
  9. Andreas von Deimling,
  10. Per thor Straten,
  11. Cecile Gouttefangeas,
  12. Judith R. Kroep,
  13. Francisco Martínez-Ricarte,
  14. Hideo Okada,
  15. Christian H. Ottensmeier,
  16. Berta Ponsati,
  17. Hans S. Poulsen,
  18. Stefan Stevanovic,
  19. Ghazaleh Tabatabai,
  20. Hans-Georg Rammensee,
  21. Ugur Sahin,
  22. Dominik Maurer, and
  23. Regina Mendrzyk
  1. Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.
Previous
Back to top
Cancer Immunology Research: 7 (2 Supplement)
February 2019
Volume 7, Issue 2 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma
Alexander Ulges, Norbert Hilf, Wolfgang Wick, Michael Platten, Pierre-Yves Dietrich, Katrin Frenzel, Arie Admon, Sjoerd S.H. van der Burg, Andreas von Deimling, Per thor Straten, Cecile Gouttefangeas, Judith R. Kroep, Francisco Martínez-Ricarte, Hideo Okada, Christian H. Ottensmeier, Berta Ponsati, Hans S. Poulsen, Stefan Stevanovic, Ghazaleh Tabatabai, Hans-Georg Rammensee, Ugur Sahin, Dominik Maurer and Regina Mendrzyk
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A020; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma
Alexander Ulges, Norbert Hilf, Wolfgang Wick, Michael Platten, Pierre-Yves Dietrich, Katrin Frenzel, Arie Admon, Sjoerd S.H. van der Burg, Andreas von Deimling, Per thor Straten, Cecile Gouttefangeas, Judith R. Kroep, Francisco Martínez-Ricarte, Hideo Okada, Christian H. Ottensmeier, Berta Ponsati, Hans S. Poulsen, Stefan Stevanovic, Ghazaleh Tabatabai, Hans-Georg Rammensee, Ugur Sahin, Dominik Maurer and Regina Mendrzyk
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A020; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A020
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement